US FDA approves first 3D printed pills

Image
ANI London
Last Updated : Aug 05 2015 | 1:22 PM IST

After approving 3D printed medical devices, the US Food and Drug Administration has now given green light to the production of 3D-printed pill.

It is being said that the new drug which is dubbed Spritam was developed by Aprecia Pharmaceuticals to control seizures brought on by epilepsy and they claim that printing the drug means that they could pack up to 1,000 milligrams into an individual tablet, reported the BBC.

Further, the company also claimed that they have developed a separate technology known as ZipDose that makes high-dose medications easier to swallow.

According to experts, being able to 3D print a tablet offers the potential to create bespoke drugs based on the specific needs of patients, rather than having a one product fits all approach.

Talking about the approval, lecturer Mohamed Albed Alhnan said that for the last 50 years, tablets have been manufactured in factories and shipped to hospitals but for the first time this process would help them in producing tablets that are much closer to the patient.

He added that it would mean that medical institutions could adjust the dose for individual patients with just a simple tweak to the software before printing.

According to the organisation, Spritam will be launched in the first quarter of 2016.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 05 2015 | 1:11 PM IST

Next Story